Product category:
Clinical chemistry analysis
News Release from: Olympus Life Science Europa | Subject: AmpliGrid
Edited by the Laboratorytalk Editorial
Team on 01 June 2007
Analysis of genetic material during
pregnancy
Advalytix, a subsidiary of Olympus Life and Material Science Europa, and the Medical University of Graz, are cooperating on novel prenatal diagnostic technologies
Together the companies are testing a new method for the genetic analysis of foetal cells from maternal blood Using the non-invasive AmpliGrid method, hereditary diseases and trisomies, such as Down's Syndrome, can be diagnosed consistently and without risk to mother or baby, even at an early stage of pregnancy
This article was originally published on Laboratorytalk on 16 Jul 2001 at 8.00am (UK)
Related stories
Microscope protects electronic components
New Olympus BX41M-ESD microscope for materials microscopy allows safe examination of electrostatically sensitive samples
Flexible system for materials microscopy
New Olympus BX2 series microscope systems for materials and metallurgical studies provides unprecedented flexibility through modular design approach
The Advalytix AmpliGrid methodology is the first technology to enable the targeted selection and analysis of single foetal cells from maternal blood.
This creates a safe and cost effective alternative to invasive tests such as amniocentesis and chorionic villi biopsies.
At present, the AmpliGrid method is in the test phase at the University of Graz and is planned to be ready for market launch in two to three years.
Further reading
Infrared metallurgical microscopy
A new system for infrared observation has been developed by Olympus for use with the BX51 metallurgical microscope
Praise for ergonomic microscope
Since its launch in May 2001, the Olympus BX45 has become widely acknowledged as a significant step forward in microscope ergonomy, particularly suitable for screening applications
Performance objectives from Olympus
The BX51 and BX61 high performance research microscopes boast an expanded range of specialist imaging applications, to give microscopists more flexibility than ever before
Invasive tests in pregnancy are risky.
Since the AmpliGrid method only requires maternal blood, it eliminates the difficulties associated with the present hereditary disease diagnosis methods.
Until now, it has been impossible to enrich these rare cells (about 1-10 cells per ml) to a high enough degree of purity.
Consequently, results of analyses are generally an un-interpretable mix of maternal and foetal genetic material.
Therefore in order to extract foetal cells only, prenatal diagnoses protocols presently rely on invasive methods such as amniocentesis.
These invasive methods though can lead to complications, such as an excessive loss of amniotic fluid, haemorrhages or injuries to the womb.
Furthermore, one in every 200 procedures leads to miscarriage.
AmpliGrid enables single cell analysis for the first time.
The AmpliGrid method developed by Advalytix uses foetal cells from the maternal blood for the diagnosis.
These are enriched and then analysed individually using modern molecular diagnostic methods.
The foetal cells are reliably selected and analysed without mixing of the mother's genetic material.
As a result diagnosis of trisomies and hereditary diseases, such as cystic fibrosis, is risk-free for both mother and foetus.
"Advalytix has succeeded in linking imaging-based and molecular biological analyses at the cellular level", explains Wolfgang Mann, project manager at Advalytix.
"This is a decisive breakthrough for routine testing of individual cells in all areas of medical diagnostics".
Advalytix and the Medical University of Graz are now cooperating on the 'in-practice' testing of this non-invasive procedure.
The university is supplying the enriched cell material, while Advalytix is validating the AmpliGrid technology based on these samples.
"This is a future oriented method, which offers a realistic perspective for the broadly based use of molecular genetic prenatal diagnostics ", explains Peter Sedlmayr from the Institute for Cell Biology, Histology and Embryology at the Centre for Molecular Medicine.
"The individual risk of a genetic disorder in the foetus is generally too slight in a young woman to justify an invasive operation.
"Theoretically, all pregnant women could benefit from the use of an effective molecular genetic analysis of foetal cells on a non-invasive basis using the AmpliGrid technology.
"Minimising the risk of such procedures is of great significance, especially in diagnostics".
Prenatal diagnostics for recognition of hereditary diseases.
Prenatal diagnostic procedures detect diseases and malformations before birth.
In particular, they provide information on the presence of hereditary diseases and trisomy of chromosomes 13, 18 and 21.
Trisomy 21 is commonly known as Down's Syndrome and is the most frequent trisomy-related disorder throughout the world, occurring at a rate of one in 600 births (on average).
Among the traditional invasive procedures used to investigate pathological changes in foetal genetic material are chorionic villi biopsies and amniocentesis.
Both methods carry significant risk of miscarriage and put stress on the pregnancy, both through the operation themselves and the long wait for results.
These risks and stresses are eliminated by the AmpliGrid technology, which guarantees safe and rapid diagnostics relieving the stress on prospective parents and the doctors. Request a free brochure from Olympus Life Science Europa ...
• Olympus Life Science Europa: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
